(0.14%) 5 107.32 points
(0.25%) 38 335 points
(0.05%) 15 935 points
(-0.48%) $83.45
(2.44%) $1.970
(-0.11%) $2 344.60
(-0.74%) $27.33
(2.39%) $944.10
(0.05%) $0.935
(0.00%) $11.02
(-0.19%) $0.799
(1.92%) $93.64
@ $3.11
发出时间: 15 Feb 2024 @ 02:43
回报率: -15.57%
上一信号: Feb 15 - 00:27
上一信号:
回报率: 3.15 %
Live Chart Being Loaded With Signals
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology...
Stats | |
---|---|
今日成交量 | 19 040.00 |
平均成交量 | 1.54M |
市值 | 97.25M |
EPS | $0 ( 2024-03-12 ) |
下一个收益日期 | ( $-0.730 ) 2024-06-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.430 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-15 | O'neill Vincent | Sell | 2 250 | Restricted Stock Units |
2024-03-15 | O'neill Vincent | Buy | 2 250 | Common Stock |
2024-04-04 | O'neill Vincent | Sell | 165 | Common Stock |
2024-03-14 | O'neill Vincent | Sell | 521 | Restricted Stock Units |
2024-03-14 | O'neill Vincent | Buy | 521 | Common Stock |
INSIDER POWER |
---|
-8.71 |
Last 87 transactions |
Buy: 187 774 | Sell: 228 648 |
BioXcel Therapeutics Inc 财务报表
Annual | 2023 |
营收: | $1.38M |
毛利润: | $-198 000 (-14.35 %) |
EPS: | $-6.15 |
FY | 2023 |
营收: | $1.38M |
毛利润: | $-198 000 (-14.35 %) |
EPS: | $-6.15 |
FY | 2022 |
营收: | $375 000 |
毛利润: | $355 000 (94.67 %) |
EPS: | $-6.13 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $0 |
Financial Reports:
No articles found.
BioXcel Therapeutics Inc
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。